XML 28 R17.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting
9 Months Ended
Sep. 30, 2025
Segment Reporting  
Segment Reporting

10. Segment Reporting

Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business in one operating segment related to the development of clinical and preclinical product candidates for neurodegenerative disorders, such as Alzheimer’s disease and DLB. The Company’s Chief Executive Officer (“CEO”) serves as the CODM.

The CEO manages and allocates resources to the operations of the Company on a consolidated basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company’s strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, cash forecasting, allocating resources and setting incentive targets. The CEO bases this assessment on the Company’s consolidated net loss. The measure of segment assets is reported on the consolidated balance sheets as total assets.

The table below is a summary of the segment loss, including significant segment expenses:

    

Nine Months Ended September 30, 

2025

2024

Grant income

$

13,407

$

16,516

Less:

 

 

Clinical programs

16,486

22,312

R&D Personnel costs(1)

6,221

7,520

Preclinical programs

262

784

Manufacturing

1,901

1,926

Other research and development expenses

222

176

General and administrative expenses(2)

7,307

7,311

Equity-based compensation

1,729

3,214

Other segment items(3)

 

(577)

 

(598)

Segment and consolidated net loss

$

(20,144)

$

(26,129)

(1) R&D Personnel costs exclude equity-based compensation

(2) General and administrative expenses exclude equity-based compensation

(3) Other segment items include, Other income, net, Interest expense and Loss on currency translation from liquidation of subsidiary.